V. Montheil

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

P. Hérait, F. Goldwasser, V. Girre, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing

F. Goldwasser, C. Tlemsani, I. Colombet, 2017, BMC Palliative Care.

Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients

F. Goldwasser, Cécile Jaeger, I. Colombet, 2012, BMJ Supportive & Palliative Care.

Transfusion de globules rouges en situation oncologique palliative

F. Goldwasser, J. Alexandre, V. Montheil, 2016 .

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

E. Raymond, P. Hérait, G. Deplanque, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience

O. Mir, F. Goldwasser, S. Ropert, 2009, Anti-cancer drugs.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

E. Raymond, P. Hérait, G. Deplanque, 2012 .

Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients.

F. Goldwasser, A. Tesnière, H. Mosnier-Pudar, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making.

F. Goldwasser, C. Tlemsani, I. Colombet, 2015, The oncologist.

Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience

O. Mir, F. Goldwasser, S. Ropert, 2009, Anti-cancer drugs.